Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2
A phase 3 trial of Disitamab vedotin, Pembrolizumab, Gemcitabine, Cisplatin and Carboplatin in bladder & urothelial cancer, run by Seagen, a wholly owned subsidiary of Pfizer, active and no longer recruiting.
Overview
Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 is a phase 3 interventional study registered as NCT05911295 by Seagen, a wholly owned subsidiary of Pfizer, with 412 participants enrolled, started 2023-09-22 and due to reach its primary completion in 2027-01-29. Interventions recorded: disitamab vedotin, pembrolizumab, gemcitabine, cisplatin and carboplatin.
Similar pages
not linked directly; found by shared links- TrialA Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma
Shares RemeGen, Gemcitabine, Cisplatin, Carboplatin and the tag pipeline.
- TrialA Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
Shares Disitamab vedotin, Merck & Co. (MSD), Bladder & urothelial cancer, Pembrolizumab and the tag pipeline.
- TrialTo Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2
Shares RemeGen, Disitamab vedotin, Bladder & urothelial cancer and the tag pipeline.
- TrialPhase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
Shares Gemcitabine, Cisplatin, Carboplatin, Bladder & urothelial cancer and the tag pipeline.
- TrialEfficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)
Shares Gemcitabine, Cisplatin, Merck & Co. (MSD), Bladder & urothelial cancer and the tag pipeline.
- TrialA Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Shares Gemcitabine, Cisplatin, Merck & Co. (MSD), Carboplatin and the tag pipeline.
- Trial9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer
Shares Gemcitabine, Cisplatin, Carboplatin, Bladder & urothelial cancer and the tag pipeline.
- TrialStudy BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)
Shares Gemcitabine, Cisplatin, Carboplatin, Bladder & urothelial cancer and the tag pipeline.